Previous close | 2.4400 |
Open | 2.4600 |
Bid | 2.5300 x 500 |
Ask | 2.6100 x 1000 |
Day's range | 2.3000 - 2.6800 |
52-week range | 0.3330 - 20.9000 |
Volume | |
Avg. volume | 2,627,211 |
Market cap | 254.83M |
Beta (5Y monthly) | 0.66 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.9200 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.25 |
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, from 3:00-3:40 PM Eastern Time. Company management will also participate in virtual one-on-one meetings with investors during the conference. The live audio webcast of the event will be available to investors and other interested p
Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.